Bionano Genomics Stock Set to Reverse Split on Monday, January 27th (NASDAQ:BNGO)

Bionano Genomics, Inc. (NASDAQ:BNGO)’s stock is scheduled to reverse split on the morning of Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Price Performance

Bionano Genomics stock traded down $0.05 during trading hours on Thursday, reaching $0.13. 31,894,418 shares of the stock were exchanged, compared to its average volume of 19,639,521. The stock has a 50 day moving average of $0.23 and a two-hundred day moving average of $0.37. Bionano Genomics has a twelve month low of $0.13 and a twelve month high of $1.36. The company has a current ratio of 1.43, a quick ratio of 0.99 and a debt-to-equity ratio of 0.07. The company has a market cap of $15.47 million, a P/E ratio of -0.06 and a beta of 2.22.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new position in shares of Bionano Genomics during the second quarter worth $1,138,000. Geode Capital Management LLC increased its holdings in Bionano Genomics by 47.3% in the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares during the period. GSA Capital Partners LLP bought a new position in Bionano Genomics during the 3rd quarter worth $46,000. Finally, Carret Asset Management LLC lifted its holdings in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the period. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.